{"disease":{"id":"merkel-cell-carcinoma","name":"Merkel cell carcinoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":5,"pipeline_drug_count":0,"trial_count":17},"drugs":{"marketed":[{"drug_id":"avelumab","indication_name":"Merkel cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bavencio","generic_name":"avelumab","company_name":"Merck KGaA","drug_phase":"marketed","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":69,"revenue":"400","mechanism":"Bavencio blocks the PD-L1 protein, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"chembl-chembl3833373","indication_name":"Metastatic Merkel Cell Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVELUMAB","company_name":"","drug_phase":"marketed","molecular_target":"PD-L1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Avelumab binds to PD-L1, blocking its interaction with PD-1 and B7.1 receptors, restoring immune responses against tumors."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Merkel cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"bavencio","indication_name":"Merkel cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bavencio","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Programmed cell death 1 ligand 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"retifanlimab-dlwr","indication_name":"Merkel cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ZYNYZ","generic_name":"RETIFANLIMAB-DLWR","company_name":"INCYTE CORP","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"retifanlimab","indication_name":"Merkel cell carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zynyz","generic_name":"RETIFANLIMAB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Zynyz works by blocking the PD-1 receptor on immune cells, allowing them to recognize and attack cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03210935","title":"French National Database of Rare Dermatological Cancers","phase":"","overall_status":"UNKNOWN","enrollment_count":9000,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT06536257","title":"Personalised Immunotherapy Platform","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Melanoma Institute Australia","has_results":false},{"nct_id":"NCT03583528","title":"DOTATOC PET/CT for Imaging NET Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT05078047","title":"Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":646,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT05429866","title":"Immunological Variables Associated to ICI Toxicity in Cancer Patients","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":441,"lead_sponsor_name":"Jules Bordet Institute","has_results":false},{"nct_id":"NCT03712605","title":"Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":280,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03935893","title":"Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Udai Kammula","has_results":false},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04242199","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT04157985","title":"Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Dan Zandberg","has_results":false},{"nct_id":"NCT06047379","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Neonc Technologies, Inc.","has_results":false},{"nct_id":"NCT03074513","title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":133,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05269381","title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04291885","title":"Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":122,"lead_sponsor_name":"Melanoma and Skin Cancer Trials Limited","has_results":false},{"nct_id":"NCT07080242","title":"Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT06947928","title":"Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":118,"lead_sponsor_name":"TuHURA Biosciences, Inc.","has_results":false},{"nct_id":"NCT04234113","title":"Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":115,"lead_sponsor_name":"SOTIO Biotech AG","has_results":true},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03599713","title":"A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT04272034","title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":105,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT03271372","title":"Adjuvant Avelumab in Merkel Cell Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":101,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT06223659","title":"EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02479698","title":"Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03545334","title":"Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT04916002","title":"A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":77,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT04260802","title":"A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":73,"lead_sponsor_name":"Ocellaris Pharma, Inc.","has_results":false},{"nct_id":"NCT07215988","title":"Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a \"Filter\" Observational Study","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02978625","title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":68,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05253144","title":"Comparing Radical Surgery and Radical Radiotherapy as First Definitive Treatment for Primary MCC","phase":"NA","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"University of Birmingham","has_results":false},{"nct_id":"NCT03435640","title":"REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":64,"lead_sponsor_name":"Nektar Therapeutics","has_results":true},{"nct_id":"NCT07115043","title":"A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06444815","title":"A Study of VET3-TGI in Patients With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"KaliVir Immunotherapeutics","has_results":false},{"nct_id":"NCT02643303","title":"A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Ludwig Institute for Cancer Research","has_results":true},{"nct_id":"NCT03684785","title":"Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Exicure, Inc.","has_results":false},{"nct_id":"NCT05859074","title":"A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03783078","title":"Pembrolizumab (MK-3475) as First-line Therapy for Advanced Merkel Cell Carcinoma (MK-3475-913)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03370861","title":"How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes","phase":"","overall_status":"TERMINATED","enrollment_count":54,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT05100095","title":"Hypofractionated Radiation Therapy for Merkel Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05947500","title":"Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03071406","title":"Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT02267603","title":"Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04596033","title":"TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":49,"lead_sponsor_name":"Genocea Biosciences, Inc.","has_results":false},{"nct_id":"NCT03629756","title":"A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Arcus Biosciences, Inc.","has_results":false},{"nct_id":"NCT03228667","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":false},{"nct_id":"NCT03652077","title":"A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT03841110","title":"FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Fate Therapeutics","has_results":false},{"nct_id":"NCT04725331","title":"A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Transgene","has_results":false},{"nct_id":"NCT03901573","title":"High-Risk Skin Cancers With Atezolizumab Plus NT-I7","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"NeoImmuneTech","has_results":true},{"nct_id":"NCT07285044","title":"The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":27,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03458117","title":"T-VEC in Non-melanoma Skin Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"University of Zurich","has_results":false}],"total":50},"guidelines":[{"drug_id":"avelumab","guideline_body":"FDA label","recommendation":"BAVENCIO (avelumab) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}